Literature DB >> 25968345

Effect of treatment with baicalein on the intracerebral tumor growth and survival of orthotopic glioma models.

Fu-Rong Wang1, Yong-Sheng Jiang.   

Abstract

Baicalein, a widely used Chinese herbal medicine, has been proved as a promising chemopreventive compound for many cancers. The aim of this work was to assess the anti-tumor effect of baicalein in the orthotopic glioma models. It was found that treatment of mice with U87 gliomas with baicalein (20 and 40 mg/kg/day, i.p.) significantly inhibited the intracerebral tumor growth and prolonged the survival. Furthermore, treatment with baicalein suppressed cell proliferation, promoted apoptosis, and arrested cell cycle in U87 gliomas. In addition, treatment with baicalein reduced tumor permeability, attenuated edema of tumors and brains, and improved tight junctions in gliomas. Finally, treatment with baicalein reduced the expression of HIF-1α, VEGF, and VEGFR2 in U87 gliomas. In addition, treatment with baicalein also markedly suppressed tumor growth and prolonged the survival of rats with 9L gliomas. In conclusion, baicalein has an obvious anti-tumor activity in the orthotopic glioma models. Our results suggested that treatment with baicalein might be an effective therapy for recurrent malignant brain cancers through suppressing tumor growth and alleviating edema.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25968345     DOI: 10.1007/s11060-015-1804-3

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  34 in total

1.  Baicalein alleviates diabetic peripheral neuropathy through inhibition of oxidative-nitrosative stress and p38 MAPK activation.

Authors:  Roman Stavniichuk; Viktor R Drel; Hanna Shevalye; Yury Maksimchyk; Tamara M Kuchmerovska; Jerry L Nadler; Irina G Obrosova
Journal:  Exp Neurol       Date:  2011-04-16       Impact factor: 5.330

2.  Immunohistochemical demonstration of serum proteins in human cerebral gliomas.

Authors:  R J Seitz; W Wechsler
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

3.  Baicalein induces G1 arrest in oral cancer cells by enhancing the degradation of cyclin D1 and activating AhR to decrease Rb phosphorylation.

Authors:  Ya-Hsin Cheng; Lih-Ann Li; Pinpin Lin; Li-Chuan Cheng; Chein-Hui Hung; Nai Wen Chang; Chingju Lin
Journal:  Toxicol Appl Pharmacol       Date:  2012-07-20       Impact factor: 4.219

Review 4.  Emerging molecular mechanisms of brain tumour oedema.

Authors:  M C Papadopoulos; S Saadoun; D C Davies; B A Bell
Journal:  Br J Neurosurg       Date:  2001-04       Impact factor: 1.596

5.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

6.  Disruption of hepatocellular tight junctions by vascular endothelial growth factor (VEGF): a novel mechanism for tumor invasion.

Authors:  Marcus Schmitt; Axel Horbach; Ralf Kubitz; Andrea Frilling; Dieter Häussinger
Journal:  J Hepatol       Date:  2004-08       Impact factor: 25.083

Review 7.  VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer.

Authors:  Elizabeth R Gerstner; Dan G Duda; Emmanuelle di Tomaso; Peter A Ryg; Jay S Loeffler; A Gregory Sorensen; Percy Ivy; Rakesh K Jain; Tracy T Batchelor
Journal:  Nat Rev Clin Oncol       Date:  2009-04       Impact factor: 66.675

8.  Intracarotid infusion of bradykinin selectively increases blood-tumor permeability in 9L and C6 brain tumors.

Authors:  T Nomura; T Inamura; K L Black
Journal:  Brain Res       Date:  1994-10-03       Impact factor: 3.252

9.  N -butyldeoxynojirimycin reduces growth and ganglioside content of experimental mouse brain tumours.

Authors:  M K Ranes; M El-Abbadi; M G Manfredi; P Mukherjee; F M Platt; T N Seyfried
Journal:  Br J Cancer       Date:  2001-04-20       Impact factor: 7.640

10.  Inhibition of 12/15-lipoxygenase by baicalein induces microglia PPARβ/δ: a potential therapeutic role for CNS autoimmune disease.

Authors:  J Xu; Y Zhang; Y Xiao; S Ma; Q Liu; S Dang; M Jin; Y Shi; B Wan; Y Zhang
Journal:  Cell Death Dis       Date:  2013-04-04       Impact factor: 8.469

View more
  7 in total

1.  Correlation between VEGFR2 rs2071559 polymorphism and glioma risk among Chinese population.

Authors:  Guo-Zheng Xu; Ying Liu; Yi Zhang; Jing Yu; Bo Diao
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  Baicalein inhibits pancreatic cancer cell proliferation and invasion via suppression of NEDD9 expression and its downstream Akt and ERK signaling pathways.

Authors:  Rong-Tao Zhou; Mei He; Ze Yu; Yang Liang; Yuzhe Nie; Sheng Tai; Chun-Bo Teng
Journal:  Oncotarget       Date:  2017-04-07

Review 3.  Flavonoids Targeting HIF-1: Implications on Cancer Metabolism.

Authors:  Marek Samec; Alena Liskova; Lenka Koklesova; Sandra Mersakova; Jan Strnadel; Karol Kajo; Martin Pec; Kevin Zhai; Karel Smejkal; Sepideh Mirzaei; Kiavash Hushmandi; Milad Ashrafizadeh; Luciano Saso; Aranka Brockmueller; Mehdi Shakibaei; Dietrich Büsselberg; Peter Kubatka
Journal:  Cancers (Basel)       Date:  2021-01-03       Impact factor: 6.639

Review 4.  Regulation of Cell Signaling Pathways and Non-Coding RNAs by Baicalein in Different Cancers.

Authors:  Ammad Ahmad Farooqi; Gulnara Kapanova; Sundetgali Kalmakhanov; Gulnur Tanbayeva; Kairat S Zhakipbekov; Venera S Rakhmetova; Marat K Syzdykbayev
Journal:  Int J Mol Sci       Date:  2022-07-29       Impact factor: 6.208

Review 5.  Intracellular Pathways and Mechanisms of Colored Secondary Metabolites in Cancer Therapy.

Authors:  Ani-Simona Sevastre; Elena Victoria Manea; Oana Stefana Popescu; Daniela Elise Tache; Suzana Danoiu; Veronica Sfredel; Ligia Gabriela Tataranu; Anica Dricu
Journal:  Int J Mol Sci       Date:  2022-09-01       Impact factor: 6.208

Review 6.  When Natural Compounds Meet Nanotechnology: Nature-Inspired Nanomedicines for Cancer Immunotherapy.

Authors:  Linna Yu; Yi Jin; Mingjie Song; Yu Zhao; Huaqing Zhang
Journal:  Pharmaceutics       Date:  2022-07-30       Impact factor: 6.525

7.  Borcalein: a Carborane-Based Analogue of Baicalein with 12-Lipoxygenase-Independent Toxicity.

Authors:  Robert Kuhnert; Lydia Kuhnert; Menyhárt-B Sárosi; Sven George; Dijana Draca; Svetlana Paskas; Bettina Hofmann; Dieter Steinhilber; Walther Honscha; Sanja Mijatović; Danijela Maksimović-Ivanić; Evamarie Hey-Hawkins
Journal:  ChemMedChem       Date:  2021-11-11       Impact factor: 3.540

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.